Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-12-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with
Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered
once a day (QD) as a single agent and in combination with dexamethasone.